Company news
Compugen Ltd. news in 2023
Compugen Ltd.'s news releases, calls and decks from 2023, newest first.
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
December 18, 2023
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
December 18, 2023
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
December 18, 2023
Compugen Reports Third Quarter 2023 Results
November 6, 2023
Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
November 5, 2023
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
November 2, 2023
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer
October 30, 2023
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023
October 23, 2023
Compugen to Present at Single Cell Genomics 2023 Meeting
October 2, 2023
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
October 1, 2023
Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023
September 26, 2023
Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 30, 2023
Compugen Reports Second Quarter 2023 Results
August 6, 2023
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
July 23, 2023
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party
July 16, 2023
Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study
June 21, 2023
Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer
June 4, 2023
Compugen Reports First Quarter 2023 Results
May 14, 2023
Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023
May 10, 2023
Compugen to Present at the JMP Securities Life Sciences Conference
May 8, 2023
Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023
April 30, 2023
Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023
April 26, 2023
Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting
April 25, 2023
Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023
March 14, 2023
Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
March 7, 2023
Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study
March 5, 2023
Compugen Reports Fourth Quarter and Full Year 2022 Results
February 26, 2023
Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3
February 13, 2023
Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023
February 12, 2023
Compugen to Present at the SVB Securities Global Biopharma Conference
February 8, 2023
Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview
January 22, 2023
Calls in 2023
Decks in 2023
- Technical Presentation (May 2023)
Technical · 19 slides · May 23, 2023